Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Avonex And Other Beta Interferons May Avoid Black Box Warning

Executive Summary

Avonex (interferon beta-1a) labeling will not include a black box warning despite an earlier request by FDA, Biogen said during an earnings call July 17.

You may also be interested in...



Biogen Sets Amevive Three Year Revenue Goal At $500 Mil.

Biogen expects revenue for the psoriasis treatment Amevive could be $500 mil. over three years

Biogen Sets Amevive Three Year Revenue Goal At $500 Mil.

Biogen expects revenue for the psoriasis treatment Amevive could be $500 mil. over three years

Serono Will File Rebif vs. Avonex 6-Month Data After June Neurology Meeting

Serono will submit six-month results from the Rebif vs. Avonex head-to-head study to FDA after the company's presentation at the World Congress of Neurology meeting in London June 22.

Related Content

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel